Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study

Por Veronesi, Andrea, Miolo, GianMaria, Magri, Maria D, Crivellari, Diana, Scalone, Simona, Bidoli, Ettore, Lombardi, Davide
Publicado em 2010

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

Por Tuzi, Alessandro, Lombardi, Davide, Crivellari, Diana, Militello, Loredana, Perin, Tiziana, La Grassa, Manuela, Massarut, Samuele, Veronesi, Andrea
Publicado em 2013

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neo...

Por Miolo, Gianmaria, Muraro, Elena, Caruso, Donatella, Crivellari, Diana, Ash, Anthony, Scalone, Simona, Lombardi, Davide, Rizzolio, Flavio, Giordano, Antonio, Corona, Giuseppe
Publicado no Oncotarget (2016)

Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases

Por Viel Alessandra, Dolcetti Riccardo, Scuderi Cristina, Zanetti Martina, Lombardi Davide, Magri Maria D, Giacomi Clelia de, Veronesi Andrea, Crivellari Diana, Bidoli Ettore, Boiocchi Mauro
Publicado em 2005-07-01

Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases

Por Veronesi, Andrea, Giacomi, Clelia de, Magri, Maria D, Lombardi, Davide, Zanetti, Martina, Scuderi, Cristina, Dolcetti, Riccardo, Viel, Alessandra, Crivellari, Diana, Bidoli, Ettore, Boiocchi, Mauro
Publicado em 2005

Adjuvant!(©) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breas...

Por Paridaens, Robert J., Gelber, Shari, Cole, Bernard F., Gelber, Richard D., Thürlimann, Beat, Price, Karen N., Holmberg, Stig B., Crivellari, Diana, Coates, Alan S., Goldhirsch, Aron
Publicado em 2010

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial...

Por Thürlimann, Beat, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Colleoni, Marco, Collins, John, Forbes, John F., Castiglione-Gertsch, Monica, Coates, Alan S., Goldhirsch, Aron
Publicado em 2008

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Por Metzger-Filho, Otto, Sun, Zhuoxin, Viale, Giuseppe, Price, Karen N., Crivellari, Diana, Snyder, Raymond D., Gelber, Richard D., Castiglione-Gertsch, Monica, Coates, Alan S., Goldhirsch, Aron, Cardoso, Fatima
Publicado em 2013

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

Por Muraro, Elena, Martorelli, Debora, Turchet, Elisa, Miolo, Gianmaria, Scalone, Simona, Comaro, Elisa, Talamini, Renato, Mastorci, Katy, Lombardi, Davide, Perin, Tiziana, Carbone, Antonino, Veronesi, Andrea, Crivellari, Diana, Dolcetti, Riccardo
Publicado em 2011

Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adj...

Por Colleoni, Marco, Cole, Bernard F., Viale, Giuseppe, Regan, Meredith M., Price, Karen N., Maiorano, Eugenio, Mastropasqua, Mauro G., Crivellari, Diana, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Gusterson, Barry A.
Publicado em 2010

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

Por Miolo, Gianmaria, Muraro, Elena, Martorelli, Debora, Lombardi, Davide, Scalone, Simona, Spazzapan, Simon, Massarut, Samuele, Perin, Tiziana, Viel, Elda, Comaro, Elisa, Talamini, Renato, Bidoli, Ettore, Turchet, Elisa, Crivellari, Diana, Dolcetti, Riccardo
Publicado no BMC Cancer (2014)

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Canc...

Por Pagani, Olivia, Gelber, Shari, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron
Publicado em 2008

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: the CASA randomized...

Por Crivellari, Diana, Gray, Kathryn P, Dellapasqua, Silvia, Puglisi, Fabio, Ribi, Karin, Price, Karen N, Láng, István, Gianni, Lorenzo, Spazzapan, Simon, Pinotti, Graziella, Lüthi, Jean-Marc, Gelber, Richard D, Regan, Meredith M, Colleoni, Marco, Castiglione-Gertsch, Monica, Maibach, Rudolf, Rabaglio, Manuela, Coates, Alan S, Goldhirsch, Aron
Publicado em 2013

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Por Pagani, Olivia, Regan, Meredith M., Walley, Barbara A., Fleming, Gini F., Colleoni, Marco, Láng, István, Gomez, Henry L., Tondini, Carlo, Burstein, Harold J., Perez, Edith A., Ciruelos, Eva, Stearns, Vered, Bonnefoi, Hervé R., Martino, Silvana, Geyer, Charles E., Pinotti, Graziella, Puglisi, Fabio, Crivellari, Diana, Ruhstaller, Thomas, Winer, Eric P., Rabaglio-Poretti, Manuela, Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Bernhard, Jürg, Luo, Weixiu, Ribi, Karin, Viale, Giuseppe, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Francis, Prudence A.
Publicado em 2014